---
title: "Recursion Pharmaceuticals (RXRX) news: class action and offering"
url: "https://aibio.space/companies/recursion-pharmaceuticals/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "RXRX class action and offering news. Recursion Pharmaceuticals news for investors: Recursion uses automated biology experiments and machine learning to find…"
---

Desk view · Opinion · Updated Oct 22, 2026

## Recursion's AI engine finally has clinical data to point to

Recursion has produced its first convincing clinical data, in a rare disease, and has cash into 2029 after a dilutive October raise. The platform's value now depends on REC-4881 getting a clear registrational path and REC-1245 confirming activity in endometrial cancer.

Read the full desk view

aibio.space Investor Rank · Opinion

**5** /10 Neutral view

First convincing clinical data and cash into 2029 after a dilutive raise, but the data are small and single-arm and the REC-4881 registrational path is unset.

- **Technology**: 1/2

- **Odds**: 0/2

- **Balance sheet**: 2/2

- **Risk**: 1/2

- **Momentum**: 1/2

Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank).

- **Technology**: **Two clinical signals now.** REC-4881 cut FAP polyp burden in 87% of patients and REC-1245 produced three partial responses, both from Recursion's own discovery engine.

- **Odds**: **Early and small.** REC-4881 is in phase 1b/2 with 15 efficacy patients, and phase 2 drugs reach phase 3 about 28.9% of the time per BIO data.

- **Balance sheet**: **Funded into 2029.** About $561 million at Sept. 30 plus a $200 million October raise, against a quarterly loss near $131 million.

- **Main risk**: **Registrational path for REC-4881.** The FDA has not yet set the trial design, and the dataset is single-arm.

- **Watch next**: **Nov.** 2 CGA-IGC data. Recursion also promises registrational path details for REC-4881 later in 2026.

## Top news on Recursion

1. 2026-10-15 Financings [Recursion raises $200 million at $3.25 a share as Sanofi options first candidate](https://aibio.space/news/recursion-raises-200-million-3-25-share-sanofi-options-first-candidate/) The company says cash now lasts into 2029. Sanofi's option on an inflammatory disease molecule triggered a $10 million milestone.
2. 2026-08-05 Legal [Recursion and its lab landlord remain in Utah court over lease construction claims](https://aibio.space/news/recursion-lab-landlord-remain-utah-court-lease-construction-claims/) Industry Office SLC sued Recursion in 2023 for breach of contract; Recursion counterclaimed for breach and fraudulent misrepresentation. Both sides are in discovery. An Exscientia class action ended in December 2025.
3. 2025-07-08 Financings [Recursion buys Rallybio's 50% ENPP1 venture stake, paying 1,457,952 shares plus cash](https://aibio.space/news/recursion-buys-rallybios-50-percent-enpp1-venture-stake-paying-1-457/) Recursion issued 1,457,952 shares to Rallybio for its half of an ENPP1 venture, with more stock and cash due on milestones. The company's share issuance is capped at 19.9% of outstanding common stock, and the 8-K names no underwriter or placement agent.

## Dates

**Nov. 2, 2026**
Additional REC-4881 data at the CGA-IGC annual meeting [Source](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000128/exhibit992-businessupdate.htm)

**Later in 2026**
More detail on the REC-4881 registrational path [Source](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000128/exhibit992-businessupdate.htm)

**2H 2026**
Additional REC-1245 phase 1 monotherapy data [Source](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000128/exhibit992-businessupdate.htm)

**2H 2027**
REC-4881 registrational trial start, pending FDA discussions, and preliminary REC-1245 endometrial cancer expansion data [Source](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000128/exhibit992-businessupdate.htm)

## The money

About $561 million in cash, cash equivalents and restricted cash at Sept. 30, 2026 (preliminary, unaudited), before a $200 million offering. Company expects cash to fund operations into 2029. [Source](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000128/exhibit992-businessupdate.htm)

## Risks on the record

- REC-4881 data come from a small, open-label, single-arm study (15 efficacy patients); four of 26 patients stopped treatment because of adverse events. [Source](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000128/exhibit992-businessupdate.htm)
- Recursion lost $131.0 million in Q2 2026 on $7.7 million of revenue and relies on partner milestones and equity raises. [Source](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000097/exhibit991-q0226.htm)
- The October 2026 offering sold 61.54 million new shares at $3.25 each. [Source](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000128/exhibit994-pricingpr.htm)

## Questions investors ask

### What is aibio.space's Investor Rank for Recursion Pharmaceuticals?

5 out of 10, our neutral view. First convincing clinical data and cash into 2029 after a dilutive raise, but the data are small and single-arm and the REC-4881 registrational path is unset. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank)

### What is Recursion's REC-4881 and how well did it work in FAP?

REC-4881 is an oral MEK1/2 inhibitor for familial adenomatous polyposis. In the TUPELO study, 87% of 15 patients had a reduction in total polyp burden after 12 weeks, with a 47% median reduction, according to an Oct. 15, 2026 update. [Source](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000128/exhibit992-businessupdate.htm)

### How much cash does Recursion have and how long will it last?

Recursion reported about $561 million in preliminary cash at Sept. 30, 2026, then raised about $200 million in an offering. It says the cash should fund operations into 2029. [Source](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000128/exhibit992-businessupdate.htm)

### What price did Recursion sell shares at in October 2026?

Recursion priced 61.54 million Class A shares at $3.25 each on Oct. 15, 2026, for gross proceeds of about $200 million. Leerink Partners, Goldman Sachs, Morgan Stanley and Evercore were joint bookrunners. [Source](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000128/exhibit994-pricingpr.htm)

### Who is the CEO of Recursion Pharmaceuticals?

Najat Khan, Ph.D., became president and CEO on Jan. 1, 2026, succeeding co-founder Chris Gibson, who became board chair. Khan was previously chief R&D and chief commercial officer. [Source](https://www.genengnews.com/topics/artificial-intelligence/stockwatch-recursion-slides-on-data-update-as-new-ceo-named/)

### What has Genentech done in its Recursion partnership?

In August 2026 Genentech exercised its first Validated Target Option in neuroscience, moving a previously unexplored target into an early discovery program. Recursion has received $216 million from Roche and Genentech to date. [Source](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000097/exhibit991-q0226.htm)

### What is the latest Recursion Pharmaceuticals (RXRX) stock news?

Our latest story on Recursion Pharmaceuticals, dated Oct 15, 2026: "Recursion raises $200 million at $3.25 a share as Sanofi options first candidate". The company says cash now lasts into 2029. Sanofi's option on an inflammatory disease molecule triggered a $10 million milestone. [Source](https://aibio.space/news/recursion-raises-200-million-3-25-share-sanofi-options-first-candidate/)

### What is Recursion Pharmaceuticals's latest stock offering or financing news?

Our latest financing story, dated Oct 15, 2026: "Recursion raises $200 million at $3.25 a share as Sanofi options first candidate". The company says cash now lasts into 2029. Sanofi's option on an inflammatory disease molecule triggered a $10 million milestone. [Source](https://aibio.space/news/recursion-raises-200-million-3-25-share-sanofi-options-first-candidate/)

### Who were the underwriters or placement agents on Recursion Pharmaceuticals's offering?

From our story: Leerink Partners, Goldman Sachs, Morgan Stanley and Evercore ran the books, and Needham was lead manager. [Source](https://aibio.space/news/recursion-raises-200-million-3-25-share-sanofi-options-first-candidate/)

### How long will Recursion Pharmaceuticals's cash last?

From our story of Oct 15, 2026: The company said the cash, together with what it already had, should fund operations into 2029. [Source](https://aibio.space/news/recursion-raises-200-million-3-25-share-sanofi-options-first-candidate/)

### How much cash does Recursion Pharmaceuticals have?

From our story of Oct 15, 2026: Cash was $753.9 million at the end of 2025 and $556.8 million at June 30, 2026, with runway guided into early 2028. [Source](https://aibio.space/news/recursion-raises-200-million-3-25-share-sanofi-options-first-candidate/)

### Is Recursion Pharmaceuticals facing a lawsuit?

Our latest legal story, dated Aug 5, 2026: "Recursion and its lab landlord remain in Utah court over lease construction claims". Industry Office SLC sued Recursion in 2023 for breach of contract; Recursion counterclaimed for breach and fraudulent misrepresentation. Both sides are in discovery. An Exscientia class action ended in December 2025. Claims in lawsuits are allegations until a court rules. [Source](https://aibio.space/news/recursion-lab-landlord-remain-utah-court-lease-construction-claims/)

### What is Recursion Pharmaceuticals's market cap?

We do not publish live share prices. In its annual report, Recursion Pharmaceuticals, Inc. put the market value of shares held by non-affiliates (public float) at $2.03 billion as of Jun 30, 2025. Source

### Is Recursion Pharmaceuticals a smaller reporting company?

SEC records list Recursion Pharmaceuticals, Inc.'s filer category as: Large accelerated filer. Source

### Where is Recursion Pharmaceuticals headquartered?

SEC records list its business address as 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101. Source

## Legal and investor matters

Checked against Recursion Pharmaceuticals filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026.

Recursion's 10-Q filed 2026-08-05 (Note 7, Legal Matters) says the company may from time to time be involved in legal proceedings arising in the normal course of business. The only matter described in that note is a lease dispute with a Utah landlord. [Source](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000098/rxrx-20260630.htm)

1. 2026-10-15 Financing Recursion prices public offering of 61.5 million shares at $3.25 Recursion signed an underwriting agreement on 2026-10-15 to sell 61,540,000 Class A shares at $3.25 each, with gross proceeds expected near $200 million. The offering was set to close 2026-10-16. In the same filing Recursion estimated cash of about $561 million at 2026-09-30 and said that, after the offering, cash should fund operations into 2029. [Recursion Form 8-K](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000128/rxrx-20261015.htm)
2. 2026-09-15 Other Recursion amends Tempus data agreement and licenses RNA model to Tempus On 2026-09-15 Recursion amended its 2023 master agreement with Tempus AI, extending the term from five to six years and removing its right to terminate for convenience. Annual license fees fall to $14,000,000 on each of the third, fourth and fifth anniversaries, with at least $4,000,000 in cash and the rest in shares or cash. Tempus also took a two-year oncology license to Recursion's RNA model for $12,000,000. [Recursion Form 8-K](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000112/rxrx-20260915.htm)
3. 2026-08-05 Litigation Utah landlord lawsuit over Recursion lab lease remains in discovery Recursion's 10-Q filed 2026-08-05 describes a lawsuit by landlord Industry Office SLC, filed 2023-06-23 in Utah state court, alleging anticipatory repudiation and breach of contract over a Salt Lake City lab and office lease. Recursion counterclaimed in September 2023, alleging breach of contract and fraudulent misrepresentation after raising construction defects. The parties are in discovery, and Recursion recorded no liability. Third District Court for Salt Lake County, State of Utah · Case 230904627 · Status: pending [Recursion Form 10-Q (2026-08-05)](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000098/rxrx-20260630.htm)
4. 2026-04-28 Governance Recursion board chair Christopher Gibson will not stand for re-election Recursion disclosed that on 2026-04-28 board chair Christopher Gibson told the company he will not stand for re-election as a Class II director at the 2026 annual meeting. The 8-K says his decision did not result from any disagreement with the company on operations, policies or practices. He remains chair and a committee member until his term expires at that meeting. [Recursion Form 8-K](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000064/rxrx-20260428.htm)
5. 2026-02-24 Financing Recursion sets up $300 million at-the-market stock program with TD Securities In February 2026 Recursion signed a sales agreement with TD Securities to sell up to $300.0 million of Class A common stock in at-the-market offerings, under a prospectus supplement dated 2026-02-24. The company sold no shares under it in the first half of 2026. The 8-K filed 2026-10-15 says it sold 23,696,330 shares under the program in the third quarter for about $86 million in net proceeds. [Recursion Form 10-Q (2026-08-05)](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000098/rxrx-20260630.htm)
6. 2025-11-04 Governance Recursion names Najat Khan CEO; Christopher Gibson becomes board chair Recursion's board appointed Najat Khan, then chief research and development officer and chief commercial officer, as chief executive officer and president on 2025-11-04, effective 2026-01-01. Also effective 2026-01-01, Christopher Gibson steps down as CEO and president and becomes board chair. Khan has been on the board since April 2024. [Recursion Form 8-K](https://www.sec.gov/Archives/edgar/data/1601830/000160183025000164/rxrx-20251104.htm)
7. 2025-06-10 Other Recursion cuts about 20% of workforce and extends cash runway into late 2027 Recursion announced on 2025-06-10 a reduction in personnel and infrastructure expected to cut its workforce by about 20%. It estimated about $11 million in charges, mostly severance in 2025, and said projected cash runway now extends into the fourth quarter of 2027. It guided 2025 cash burn below $450 million and 2026 below $390 million. [Recursion Form 8-K](https://www.sec.gov/Archives/edgar/data/1601830/000119312525138138/d80288d8k.htm)
8. 2024-11-20 Other Recursion completes all-stock acquisition of Exscientia Recursion said that on 2024-11-20 its acquisition of Exscientia became effective after the High Court of England and Wales sanctioned the scheme of arrangement on 2024-11-19. Each Exscientia ordinary share was exchanged for 0.7729 shares of Recursion Class A common stock, and Exscientia became a wholly owned subsidiary. High Court of Justice of England and Wales [Recursion Form 8-K](https://www.sec.gov/Archives/edgar/data/1601830/000160183024000217/rxrx-20241119.htm)

## Pipeline

| Program | Indication | Stage |
|---|---|---|
| REC-4881 (MEK1/2 inhibitor) | Familial adenomatous polyposis | Phase 1b/2 (TUPELO); registrational trial planned 2H 2027 [Source](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000128/exhibit992-businessupdate.htm) |
| REC-1245 (RBM39 degrader) | Solid tumors, including endometrial cancer expansion | Phase 1 (DAHLIA) [Source](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000128/exhibit992-businessupdate.htm) |
| REC-617 (CDK7 inhibitor) | Advanced solid tumors | Phase 1/2; Recursion seeking a partner [Source](https://www.genengnews.com/topics/artificial-intelligence/stockwatch-recursion-slides-on-data-update-as-new-ceo-named/) |
| Sanofi-optioned candidate (oral small molecule) | Inflammatory disease | Optioned by Sanofi; phase 1 expected 2027 [Source](https://www.sec.gov/Archives/edgar/data/0001601830/000160183026000128/exhibit992-businessupdate.htm) |

Opinion · Devil's advocate

## Fact-check-o-meter

Some gaps

Recursion's October data release is positive, but small, uncontrolled and loosely reconciled

Recursion's October 15 release and its offering prospectus supplement describe the same TUPELO and DAHLIA data, but the patient counts do not match and the liver cancer response came with toxicity the release left out. The longer cash runway rests on the new raise and about $86 million of at-the-market sales, which only the prospectus spells out. No securities litigation is disclosed.

1. Press release vs filing · weight medium Runway moves from early 2028 to 2029 on new equity **The company said:** "Expected Cash Runway Extended into 2029, including proceeds from the concurrently announced offering" [source](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000128/exhibit992-businessupdate.htm) **The record says:** The August 5 release said: "Based on current operating plans with no additional financing, the Company continues to expect its cash runway to extend into early 2028." The October prospectus supplement adds: "The preliminary cash balance includes approximately $86 million in net proceeds from the sale of 23,696,330 shares of Class A Common Stock under our at-the-market program with TD Securities (USA) LLC during the quarter ended September 30, 2026." On runway, the 10-Q says only that cash "will be sufficient to fund our operations for at least the next twelve months." [source](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000134/rxrx-finalprosuppxoct2026o.htm) **Our view:** The release does say the 2029 figure includes the offering, so this is not hidden. What it leaves out is that the $561 million Q3 cash balance already contains roughly $86 million raised through the at-the-market program. The runway extension comes mainly from new equity, and dilution comes with it. The August release also lowered 2026 cash operating expense guidance to under $375 million from under $390 million.
2. Press release vs filing · weight medium REC-4881 patient count differs between release and prospectus **The company said:** "After 12 weeks of treatment, 87% of patients (13 of 15) had reductions in total polyp burden, with a 47% median reduction" [source](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000128/exhibit992-businessupdate.htm) **The record says:** The prospectus supplement says: "With a data cutoff of September 10, 2026, we reported on sixteen (16) efficacy-evaluable patients," and "Of the 16 efficacy-evaluable patients, 87% of patients achieved reductions in total polyp burden, with a 47% median reduction in total polyp burden at week 13." It also says the 16 "reflect 4 additional efficacy-evaluable patients from the last update." [source](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000134/rxrx-finalprosuppxoct2026o.htm) **Our view:** 13 of 15 is 87%, while 87% of 16 does not come out to a whole number of patients. One of the two documents likely has a typo or uses a different counting rule. The November 2 CGA-IGC presentation should settle which denominator is right.
3. Science · weight high REC-4881 evidence is an open-label, single-arm phase 1b/2 **The company said:** "REC-4881 Phase 1b/2 Data Update: Deep, durable polyp burden reductions reproduced in the expanded adult FAP population (18+), with a 47% median reduction after 12 weeks of treatment and 85% maintaining reductions below baseline after 12 weeks off treatment." [source](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000128/exhibit992-businessupdate.htm) **The record says:** The prospectus describes "a multi-center, open-label trial" in which patients get 4 mg daily for twelve weeks, then no treatment for twelve weeks, with polyp burden "defined as the sum of all polyp diameters." ClinicalTrials.gov lists TUPELO (NCT05552755) as a non-randomized, unmasked Phase 1/2 with an estimated 67 participants, and its listed primary outcomes include safety measures alongside "Percent Change From Baseline in Polyp Burden." The release reports 4 patients discontinuing for adverse events among 26 safety-evaluable patients. [source](https://clinicaltrials.gov/study/NCT05552755) **Our view:** Reductions in a sum-of-diameters measure from a small group with no control arm are a reasonable early signal, not proof of benefit over natural history. The release plans a registrational trial for 2H 2027 "pending FDA discussions," so what FDA accepts as the endpoint is still open.
4. Science · weight medium REC-1245 response headline omits the toxicity behind the liver cancer response **The company said:** "Encouraging monotherapy activity with 2 confirmed partial responses in endometrial cancer, 1 unconfirmed response in liver cancer, and a 91.7% disease control rate (11/12) at doses ≥45 mg" [source](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000128/exhibit992-businessupdate.htm) **The record says:** The prospectus states the liver cancer patient "achieved an unconfirmed PR with a 55.9% reduction at Week 9, but withdrew from the trial due to toxicity, including Grade 3 stomatitis, Grade 4 thrombocytopenia and febrile neutropenia." Across all doses, "14 of 21 efficacy-evaluable patients (66.7%) achieved disease control at week 9," and "eight patients (26.7%) experienced Grade 3 or higher TRAEs." [source](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000134/rxrx-finalprosuppxoct2026o.htm) **Our view:** The 91.7% figure applies to 12 patients at the two highest tested doses, and the all-dose rate is lower. The 45 mg choice looks reasoned, but the expansion dose has only 10 patients behind its reported safety record, which includes two Grade 3 treatment-related events at 45 mg. This is a phase 1 dose-finding study, and the release says so.
5. Legal and disclosure record · weight low Landlord lawsuit in Utah; no securities litigation **The record says:** Note 7 of the 10-Q discloses Industry Office SLC, LLC v. Recursion Pharmaceuticals, Inc., Case No. 230904627, Third District Court for Salt Lake County, Utah, filed June 23, 2023, alleging anticipatory repudiation and breach of contract over a lab lease. Recursion filed counterclaims in September 2023. The filing says the company "had no liability recorded for these events as an unfavorable outcome was not probable" and that the parties "are currently engaged in discovery." No securities litigation or enforcement disclosed in the latest filing. [source](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000098/rxrx-20260630.htm) **Our view:** A real-estate dispute with an unquantified range of damages is the only documented matter. It is not tied to the science or the financing.

Documents we compared

- [Recursion offering and clinical update release (8-K Exhibit 99.2)](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000128/exhibit992-businessupdate.htm) 2026-10-15
- [Recursion prospectus supplement for October 2026 offering (424B5)](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000134/rxrx-finalprosuppxoct2026o.htm) 2026-10-15
- [Recursion Q2 2026 results press release (8-K Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000097/exhibit991-q0226.htm) 2026-08-05
- [Recursion Form 10-Q for the quarter ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000098/rxrx-20260630.htm) 2026-08-05
- [ClinicalTrials.gov NCT05552755 (TUPELO, REC-4881 in FAP)](https://clinicaltrials.gov/study/NCT05552755) 2026-10-23

This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply).

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:RXRX on TradingView](https://www.tradingview.com/symbols/NASDAQ-RXRX/).

## SEC filings and registration

- **SEC name**: Recursion Pharmaceuticals, Inc.

- **CIK**: 1601830

- **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836)

- **US tickers**: RXRX (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Large accelerated filer

- **Business address**: 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101

- **Phone**: (385) 269-0203

- **Shares outstanding**: 535,342,170 as of 2026-07-31 (10-Q filed 2026-08-05)

- **Former names**: Recursion Pharmaceuticals, LLC

### Recent filings (8-K and 6-K are the company's own announcements)

- [424B5](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000134/rxrx-finalprosuppxoct2026o.htm) filed 2026-10-15
- [8-K](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000128/rxrx-20261015.htm) filed 2026-10-15
- [424B5](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000126/rxrx-prelimprosuppxoct2026.htm) filed 2026-10-15
- [8-K](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000112/rxrx-20260915.htm) filed 2026-09-21
- [10-Q](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000098/rxrx-20260630.htm) filed 2026-08-05
- [8-K](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000097/rxrx-20260805.htm) filed 2026-08-05
- [8-K](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000080/rxrx-20260617.htm) filed 2026-06-18
- [10-Q](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000078/rxrx-20260331.htm) filed 2026-05-06

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001601830), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/recursion-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Recursion Pharmaceuticals (RXRX) news: class action and offering", 2026-10-31, https://aibio.space/companies/recursion-pharmaceuticals/